Synthesis, structure and anticancer properties of new biotin- and morpholine-functionalized ruthenium and osmium half-sandwich complexes.
Animals
Antineoplastic Agents
/ chemical synthesis
Biotin
/ chemistry
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Coordination Complexes
/ chemical synthesis
Crystallography, X-Ray
Density Functional Theory
Drug Screening Assays, Antitumor
Humans
Mice
Models, Molecular
Molecular Structure
Morpholines
/ chemistry
Osmium
/ chemistry
Ruthenium
/ chemistry
Anticancer complex
Cell targeting
Metallodrug
Metal–arene
shRNA profiling
Journal
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry
ISSN: 1432-1327
Titre abrégé: J Biol Inorg Chem
Pays: Germany
ID NLM: 9616326
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
05
05
2021
accepted:
15
06
2021
pubmed:
27
6
2021
medline:
30
11
2021
entrez:
26
6
2021
Statut:
ppublish
Résumé
Ruthenium (Ru) and osmium (Os) complexes are of sustained interest in cancer research and may be alternative to platinum-based therapy. We detail here three new series of ruthenium and osmium complexes, supported by physico-chemical characterizations, including time-dependent density functional theory, a combined experimental and computational study on the aquation reactions and the nature of the metal-arene bond. Cytotoxic profiles were then evaluated on several cancer cell lines although with limited success. Further investigations were, however, performed on the most active series using a genetic approach based on RNA interference and highlighted a potential multi-target mechanism of action through topoisomerase II, mitotic spindle, HDAC and DNMT inhibition.
Identifiants
pubmed: 34173882
doi: 10.1007/s00775-021-01873-9
pii: 10.1007/s00775-021-01873-9
doi:
Substances chimiques
Antineoplastic Agents
0
Coordination Complexes
0
Morpholines
0
Osmium
2E7M255OPY
Biotin
6SO6U10H04
Ruthenium
7UI0TKC3U5
morpholine
8B2ZCK305O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
535-549Informations de copyright
© 2021. Society for Biological Inorganic Chemistry (SBIC).
Références
Rosenberg B, Van Camp L, Krigas T (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205:698–699. https://doi.org/10.1038/205698a0
doi: 10.1038/205698a0
pubmed: 14287410
Galluzzi L, Senovilla L, Vitale I et al (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31:1869–1883. https://doi.org/10.1038/onc.2011.384
doi: 10.1038/onc.2011.384
pubmed: 21892204
Florea A-M, Büsselberg D (2011) Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 3:1351–1371. https://doi.org/10.3390/cancers3011351
doi: 10.3390/cancers3011351
Trondl R, Heffeter P, Kowol CR et al (2014) NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chem Sci 5:2925–2932. https://doi.org/10.1039/c3sc53243g
doi: 10.1039/c3sc53243g
Leijen S, Burgers SA, Baas P et al (2015) Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Invest New Drugs 33:201–214. https://doi.org/10.1007/s10637-014-0179-1
doi: 10.1007/s10637-014-0179-1
pubmed: 25344453
Meier-Menches SM, Gerner C, Berger W et al (2018) Structure–activity relationships for ruthenium and osmium anticancer agents—towards clinical development. Chem Soc Rev. https://doi.org/10.1039/C7CS00332C
doi: 10.1039/C7CS00332C
pubmed: 29170783
Aird RE, Cummings J, Ritchie AA et al (2002) In vitro and in vivo activity and cross resistance profiles of novel ruthenium(II) organometallic arene complexes in human ovarian cancer. Br J Cancer 86:1652–1657. https://doi.org/10.1038/sj/bjc/6600290
doi: 10.1038/sj/bjc/6600290
pubmed: 12085218
pmcid: 2746580
Scolaro C, Bergamo A, Brescacin L et al (2005) In vitro and in vivo evaluation of ruthenium(II)–arene PTA complexes. J Med Chem 48:4161–4171. https://doi.org/10.1021/jm050015d
doi: 10.1021/jm050015d
pubmed: 15943488
Peacock AFA, Habtemariam A, Ferna R et al (2006) Tuning the reactivity of osmium (II) and ruthenium (II) arene complexes under physiological conditions. J Am Chem Soc 128:1739–1748
doi: 10.1021/ja055886r
Zhang P, Sadler PJ (2017) Advances in the design of organometallic anticancer complexes. J Organomet Chem 839:5–14. https://doi.org/10.1016/j.jorganchem.2017.03.038
doi: 10.1016/j.jorganchem.2017.03.038
Needham RJ, Sanchez-Cano C, Zhang X et al (2017) In-cell activation of organo-osmium(II) anticancer complexes. Angew Chemie Int Ed 56:1017–1020. https://doi.org/10.1002/anie.201610290
doi: 10.1002/anie.201610290
Flocke LS, Trondl R, Jakupec MA, Keppler BK (2016) Molecular mode of action of NKP-1339—a clinically investigated ruthenium-based drug—involves ER- and ROS-related effects in colon carcinoma cell lines. Invest New Drugs 34:261–268. https://doi.org/10.1007/s10637-016-0337-8
doi: 10.1007/s10637-016-0337-8
pubmed: 26988975
pmcid: 4859864
Gifford JB, Huang W, Zeleniak AE et al (2016) Expression of GRP78, master regulator of the unfolded protein response, increases chemoresistance in pancreatic ductal adenocarcinoma. Mol Cancer Ther 15:1043–1052. https://doi.org/10.1158/1535-7163.MCT-15-0774
doi: 10.1158/1535-7163.MCT-15-0774
pubmed: 26939701
Neuditschko B, Legin AA, Baier D et al (2021) Interaction with ribosomal proteins accompanies stress induction of the anticancer metallodrug BOLD-100/KP1339 in the endoplasmic reticulum. Angew Chemie Int Ed 60:5063–5068. https://doi.org/10.1002/anie.202015962
doi: 10.1002/anie.202015962
Meier SM, Kreutz D, Winter L et al (2017) An organoruthenium anticancer agent shows unexpected target selectivity for plectin. Angew Chemie Int Ed 56:1–6. https://doi.org/10.1002/anie.201702242
doi: 10.1002/anie.201702242
Dong B, Song X, Kong X et al (2017) A tumor-targeting and lysosome-specific two-photon fluorescent probe for imaging pH changes in living cells. J Mater Chem B 5:988–995. https://doi.org/10.1039/c6tb02957d
doi: 10.1039/c6tb02957d
pubmed: 32263877
Andrew CL, Klemm AR, Lloyd JB (1997) Lysosome membrane permeability to amines. Biochim Biophys Acta Biomembr 1330:71–82. https://doi.org/10.1016/S0005-2736(97)00145-4
doi: 10.1016/S0005-2736(97)00145-4
Fu Y, Habtemariam A, Pizarro AM et al (2010) Organometallic osmium arene complexes with potent cancer cell cytotoxicity. J Med Chem 53:8192–8196. https://doi.org/10.1021/jm100560f
doi: 10.1021/jm100560f
pubmed: 20977192
Piao S, Amaravadi RK (2016) Targeting the lysosome in cancer. Ann N Y Acad Sci 1371:45–54. https://doi.org/10.1111/nyas.12953
doi: 10.1111/nyas.12953
pubmed: 26599426
Fehrenbacher N, Jäättelä M (2005) Lysosomes as targets for cancer therapy. Cancer Res 65:2993–2995. https://doi.org/10.1158/0008-5472.CAN-05-0476
doi: 10.1158/0008-5472.CAN-05-0476
pubmed: 15833821
Casini A, Gabbiani C, Sorrentino F et al (2008) Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. J Med Chem 51:6773–6781. https://doi.org/10.1021/jm8006678
doi: 10.1021/jm8006678
pubmed: 18834187
Mokesch S, Schwarz D, Hejl M et al (2019) Fine-tuning the activation mode of an 1,3-Indandione-based ruthenium(II)-Cymene half-sandwich complex by variation of its leaving group. Molecules 24:1–15. https://doi.org/10.3390/molecules24132373
doi: 10.3390/molecules24132373
Hao L, Zhong Y-M, Tan C-P, Mao Z-W (2021) Acidity-responsive phosphorescent metal complexes for cancer imaging and theranostic applications. J Organomet Chem. https://doi.org/10.1016/j.jorganchem.2021.121821
doi: 10.1016/j.jorganchem.2021.121821
Ren W, Han J, Uhm S et al (2015) Recent development of biotin conjugation in biological imaging, sensing, and target delivery. Chem Commun 51:10403–10418. https://doi.org/10.1039/C5CC03075G
doi: 10.1039/C5CC03075G
Muhammad N, Sadia N, Zhu C et al (2017) Biotin-tagged platinum(IV) complexes as targeted cytostatic agents against breast cancer cells. Chem Commun 53:9971–9974. https://doi.org/10.1039/c7cc05311h
doi: 10.1039/c7cc05311h
Jin S, Guo Y, Song D et al (2019) Targeting energy metabolism by a platinum(IV) prodrug as an alternative pathway for cancer suppression. Inorg Chem 58:6507–6516. https://doi.org/10.1021/acs.inorgchem.9b00708
doi: 10.1021/acs.inorgchem.9b00708
pubmed: 31013065
Babak MV, Plażuk D, Meier SM et al (2015) Half-sandwich ruthenium(II) biotin conjugates as biological vectors to cancer cells. Chemistry 21:5110–5117. https://doi.org/10.1002/chem.201403974
doi: 10.1002/chem.201403974
pubmed: 25676245
Côrte-Real L, Karas B, Brás AR et al (2019) Ruthenium-cyclopentadienyl bipyridine-biotin based compounds: synthesis and biological effect. Inorg Chem 58:9135–9149. https://doi.org/10.1021/acs.inorgchem.9b00735
doi: 10.1021/acs.inorgchem.9b00735
pubmed: 31241925
Teixeira RG, Belisario DC, Fontrodona X et al (2021) Unprecedented collateral sensitivity for cisplatin-resistant lung cancer cells presented by new ruthenium organometallic compounds. Inorg Chem Front. https://doi.org/10.1039/d0qi01344g
doi: 10.1039/d0qi01344g
Martin A. Bennett and Anthony K. Smith (1974) Arene ruthenium (II) complexes formed by dehydrogenation of Cyclo-. J Chem Soc Dalt Trans 0:233–241
Stahl SWH (1990) A new family of (arene)osmium(0) and -osmium(II) complexes. Organometallics 9:1876–1881
doi: 10.1021/om00156a029
Peacock AFA, Habtemariam A, Moggach SA et al (2007) Chloro half-sandwich osmium (II) complexes: influence of chelated N, N-ligands on hydrolysis, guanine binding, and cytotoxicity. Inorg Chem 46:2966–2967. https://doi.org/10.1021/ic062350d
doi: 10.1021/ic062350d
Morris RE, Aird RE, Del Socorro MP et al (2001) Inhibition of cancer cell growth by ruthenium(II) arene complexes. J Med Chem 44:3616–3621. https://doi.org/10.1021/jm010051m
doi: 10.1021/jm010051m
pubmed: 11606126
Higgins B, DeGraff BA, Demas JN (2005) Luminescent transition metal complexes as sensors: structural effects on pH response. Inorg Chem 44:6662–6669. https://doi.org/10.1021/ic050044e
doi: 10.1021/ic050044e
pubmed: 16156624
Chai J-D, Head-Gordon M (2008) Long-range corrected hybrid density functionals with damped atom-atom dispersion corrections. Phys Chem Chem Phys 10:6615–6620. https://doi.org/10.1039/b810189b
doi: 10.1039/b810189b
pubmed: 18989472
Weigend F, Ahlrichs R (2005) Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: design and assessment of accuracy w. Phys Chem Chem Phys 7:3297–3305
doi: 10.1039/b508541a
Weigend F (2006) Accurate Coulomb-fitting basis sets for H to Rn. Phys Chem Chem Phys 8:1057–1065. https://doi.org/10.1039/b515623h
doi: 10.1039/b515623h
pubmed: 16633586
Van LE, Baerends EJ, Snijders JG (1993) Relativistic regular two-component Hamiltonians. J Chem Phys 99:4597. https://doi.org/10.1063/1.466059
doi: 10.1063/1.466059
Glendening ED, Badenhoop JK, Reed AE et al (2013) NBO 6.0. Theor Chem Institute, Univ Wisconsin, Madison
Klose MHM, Hejl M, Heffeter P et al (2017) Post-digestion stabilization of osmium enables quantification by ICP-MS in cell culture and tissue. Analyst 142:2327–2332. https://doi.org/10.1039/c7an00350a
doi: 10.1039/c7an00350a
pubmed: 28585637
Berger G, Grauwet K, Zhang H et al (2018) Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models. Cancer Lett 416:138–148. https://doi.org/10.1016/j.canlet.2017.11.041
doi: 10.1016/j.canlet.2017.11.041
pubmed: 29246647
Jiang H, Pritchard JR, Williams RT et al (2010) A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat Chem Biol 7:1–9. https://doi.org/10.1038/nchembio.503
doi: 10.1038/nchembio.503
Pritchard JR, Bruno PM, Hemann MT, Lauffenburger DA (2013) Predicting cancer drug mechanisms of action using molecular network signatures. Mol Biosyst 9:1604–1619. https://doi.org/10.1039/c2mb25459j
doi: 10.1039/c2mb25459j
pubmed: 23287973
pmcid: 3945388
Pritchard JR, Bruno PM, Gilberta LA et al (2013) Defining principles of combination drug mechanisms of action. PNAS. https://doi.org/10.1073/pnas.1210419110
doi: 10.1073/pnas.1210419110
pubmed: 23251029
Landázuri N, Le Doux JM (2006) Complexation with chondroitin sulfate C and polybrene rapidly purifies retrovirus from inhibitors of transduction and substantially enhances gene transfer. Biotechnol Bioeng 93:146–158. https://doi.org/10.1002/bit.20697
doi: 10.1002/bit.20697
pubmed: 16240439
Bevernaegie R, Marcélis L, Laramée-Milette B et al (2018) Trifluoromethyl-substituted iridium(III) complexes: from photophysics to photooxidation of a biological target. Inorg Chem 57:1356–1367. https://doi.org/10.1021/acs.inorgchem.7b02778
doi: 10.1021/acs.inorgchem.7b02778
pubmed: 29336560
Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307–320. https://doi.org/10.1038/nrd1691
doi: 10.1038/nrd1691
pubmed: 15789122
Marloye M, Berger G, Gelbcke M, Dufrasne F (2016) A survey of the mechanisms of action of anticancer transition metal complexes. Future Med Chem. https://doi.org/10.4155/fmc-2016-0153
doi: 10.4155/fmc-2016-0153
pubmed: 27874280
Betanzos-lara S, Novakova O, Deeth RJ et al (2012) Bipyrimidine ruthenium (II) arene complexes: structure, reactivity and cytotoxicity. J Biol Inorg Chem 17:1033–1051. https://doi.org/10.1007/s00775-012-0917-9
doi: 10.1007/s00775-012-0917-9
pubmed: 22791215
Wang F, Chen H, Parsons S et al (2003) Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts. Chem A Eur J 9:5810–5820. https://doi.org/10.1002/chem.200304724
doi: 10.1002/chem.200304724
Popp J, Hanf S, Hey-Hawkins E (2019) Facile arene ligand exchange in p-cymene ruthenium(II) complexes of tertiary P-chiral ferrocenyl phosphines. ACS Omega 4:22540–22548. https://doi.org/10.1021/acsomega.9b03251
doi: 10.1021/acsomega.9b03251
pubmed: 31909337
pmcid: 6941384
Sullivan MP, Nieuwoudt MK, Bowmaker GA et al (2018) Unexpected arene ligand exchange results in the oxidation of an organoruthenium anticancer agent: the first X-ray structure of a protein–Ru(carbene) adduct. Chem Commun. https://doi.org/10.1039/C8CC02433B
doi: 10.1039/C8CC02433B
Hubig SM, Lindeman SV, Kochi JK (2000) Charge-transfer bonding in metal-arene coordination. Coord Chem Rev 200–202:831–873. https://doi.org/10.1016/S0010-8545(00)00322-2
doi: 10.1016/S0010-8545(00)00322-2
Adeniyi AA, Ajibade PA (2013) Insights into the intramolecular properties of η 6-arene-Ru-based anticancer complexes using quantum calculations. J Chem. https://doi.org/10.1155/2013/892052
doi: 10.1155/2013/892052
Bruno PM, Liu Y, Park GY et al (2017) A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med 23:461–471. https://doi.org/10.1038/nm.4291
doi: 10.1038/nm.4291
pubmed: 28263311
pmcid: 5520548
Zheng YR, Suntharalingam K, Bruno PM et al (2016) Mechanistic studies of the anticancer activity of an octahedral hexanuclear Pt(II) cage. Inorganica Chim Acta 452:125–129. https://doi.org/10.1016/j.ica.2016.03.021
doi: 10.1016/j.ica.2016.03.021
pubmed: 27818526
pmcid: 5094802
Suntharalingam K, Johnstone TC, Bruno PM et al (2013) Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways. J Am Chem Soc 135:14060–14063. https://doi.org/10.1021/ja4075375
doi: 10.1021/ja4075375
pubmed: 24041161
pmcid: 3791136
Bruno PM, Lu M, Dennis KA et al (2020) The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning. Proc Natl Acad Sci USA 117:4053–4060. https://doi.org/10.1073/pnas.1921649117
doi: 10.1073/pnas.1921649117
pubmed: 32041867
pmcid: 7049172